Black Rock Inc. Cyclo Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.23 Trillion
- Q1 2024
A detailed history of Black Rock Inc. transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 37,126 shares of CYTH stock, worth $47,521. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,126
Previous 48,444
23.36%
Holding current value
$47,521
Previous $77,000
33.77%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CYTH
# of Institutions
22Shares Held
2.16MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA854KShares$1.09 Million0.47% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$615,3063.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA397KShares$507,7220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA160KShares$204,4780.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$140,82957.89% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $10.8M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...